Peptide PilotPeptide Pilot

Dose calculator

Ipamorelin dose calculator

Convert any Ipamorelin dose into syringe units in real time, pre-filled with a 2 mg / 2 mL example.

Download Peptide PilotiPhone · Free to download

Draw on a U-100 syringe

0.02 units

Volume to draw

0.000 mL

Ipamorelin is a short-acting injectable peptide people use to trigger a clean pulse of their own growth hormone, usually for recovery, sleep, and body composition. It mimics the gut hormone ghrelin at a single receptor, which keeps GH release pulse-like and avoids meaningful spikes in cortisol or prolactin. Studies show clear short-term GH increases after each injection, which is why it's commonly stacked with CJC-1295. This page covers reconstitution math and per-injection logging cadence.

How the Ipamorelin dose calculator works

This calculator answers a simple question: given the concentration of the Ipamorelin solution already in your vial, how many syringe units does today's dose work out to? It is the second half of the reconstitution math — the first half locks in concentration, this one converts any dose mg or mcg into a clean unit count.

The formula is volume in mL equals dose mg divided by concentration mg/mL, then volume times one hundred to get units on a U-100 insulin syringe. With a 1 mg/mL Ipamorelin solution and a 0.2 mg dose, the draw is 0.20 mL or about 20 units. Type any other dose and the unit count updates in real time — no spreadsheets, no guesswork.

Inputs that genuinely matter: concentration (which only changes when you reconstitute a new vial) and dose mass. Syringe type matters too, but only because U-100 vs U-40 changes the multiplier — almost every modern insulin syringe is U-100, which is why the math defaults to that. Edge cases worth flagging: switching from mcg to mg without checking the input unit, or carrying yesterday's unit count over to a new vial that was reconstituted with a different volume of BAC water.

Most people use this calculator at two moments: when titrating a dose up or down, and when prepping a single dose before injection. The output is meant to be checked against the syringe before drawing — read the markings, confirm the unit count, then draw. The calculator is fast precisely so you can do that check every time without it feeling like a chore.

How Ipamorelin dosing is tracked

Research protocols often schedule Ipamorelin administration to coincide with the body's natural growth hormone pulses, such as late in the evening before sleep or following strenuous exercise. Cadence in these studies frequently involves daily administration, as seen in the 7-day-per-week example. To ensure precision, doses are measured using U-100 insulin syringes, which allow for accurate volume control when drawing from a reconstituted vial. For optimal signaling, doses are typically administered on an empty stomach to avoid the inhibitory effects of insulin and somatostatin on GH release.

The rationale for stacking Ipamorelin with a Growth Hormone-Releasing Hormone (GHRH) analog, such as CJC-1295 without DAC, is based on creating a powerful synergistic effect. This combination targets two distinct but complementary receptors in the pituitary gland: Ipamorelin activates the ghrelin receptor, while the GHRH analog activates its own receptor. Activating both pathways simultaneously has been studied to amplify the magnitude of the resulting GH pulse far more than either compound could alone, while still preserving the natural pulsatile pattern of release.

Research protocols designed to study ipamorelin often schedule administrations around specific metabolic states, particularly fasting. Because elevated blood glucose and subsequent insulin secretion can attenuate the GH pulse stimulated by GHS-R agonists, many study designs plan for administration in a fasted state, such as in the morning before any caloric intake or at least two to three hours after the last meal. By standardizing the prandial state, researchers can better control for variables that influence GH release. All such details, including the duration of the pre-administration fast, can be meticulously documented in a log to observe patterns with greater clarity.

Ipamorelin mechanism in plain English

Ipamorelin functions as a synthetic agonist for the ghrelin receptor, scientifically known as the growth hormone secretagogue receptor type 1a (GHSR-1a). Upon administration, it travels to the pituitary gland and binds to these receptors, mimicking the action of ghrelin, the endogenous hormone responsible for initiating GH release pulses. The activation of GHSR-1a initiates an intracellular signaling cascade that results in the synthesis and secretion of stored growth hormone from somatotroph cells.

The crucial aspect of its mechanism is its high specificity for the GHSR-1a. Unlike first- and second-generation GHRPs, Ipamorelin's molecular structure was intentionally refined to minimize or avoid interaction with other receptor systems. This selectivity prevents the downstream release of other pituitary hormones such as prolactin and ACTH, and consequently avoids stimulating the adrenal gland to produce cortisol, which are widely documented side effects of its predecessors.

The high selectivity of ipamorelin is a central aspect of its mechanism. While it functions, like other GHRPs, by mimicking the action of ghrelin, its molecular design results in a more discrete signaling cascade. Upon binding to the GHS-R1a receptor, it stimulates the pituitary somatotrophs to release a pulse of growth hormone. Unlike less selective compounds, it does not demonstrate a significant affinity for other receptors or trigger substantial cross-reactivity that would lead to a release of cortisol or prolactin at typical research dosages. This allows researchers to monitor the downstream effects attributable primarily to GH itself, providing a cleaner dataset for analysis and tracking over time.

Common Ipamorelin dose mistakes

  • Administering doses at inconsistent times of day, which compromises the ability to observe long-term trends related to its selective action.
  • Logging a combination like Ipamorelin/CJC-1295 as a single dose entry, which inevitably causes errors in vial inventory management for each separate peptide.
  • Misinterpreting the designed absence of an appetite spike as a sign that the peptide is inactive or low in potency.
  • Scheduling administration shortly after a meal containing carbohydrates or fats, thereby blunting the potential GH pulse via insulin release.
  • Failing to document the reconstitution date and diluent volume, which makes future dose calculations and expirations impossible to track accurately.
  • Assuming ipamorelin produces identical secondary hormonal effects as older compounds like GHRP-6, thereby failing to account for its selective nature in study design.
  • Not documenting the timing of administration in relation to meals, which introduces insulin fluctuations as an uncontrolled variable.
  • Neglecting to use a calculator to verify dose calculations after reconstitution, leading to inconsistent administration amounts that compromise data integrity.

Frequently asked questions about Ipamorelin dose

What is the primary distinction between Ipamorelin and GHRP-6?
The defining distinction is selectivity. Ipamorelin was developed specifically to stimulate growth hormone release with high potency while avoiding the significant increases in appetite, cortisol, and prolactin that are characteristic of older secretagogues like GHRP-6. This targeted action results from its refined molecular structure and specific binding profile.
Why is Ipamorelin often studied in combination with CJC-1295 without DAC?
This combination is studied because it targets two separate pituitary receptors to synergistically amplify GH release. Ipamorelin acts on the ghrelin receptor while CJC-1295 (no DAC) acts on the GHRH receptor. Activating both pathways at once generates a more robust GH pulse than using either peptide alone, while still honoring the body's natural pulsatile rhythm.
How many units are required for a 200 mcg dose from a 2 mg vial reconstituted with 2 mL?
A 2 mg vial holds 2,000 micrograms of peptide. When reconstituted with 2 mL of bacteriostatic water, the final concentration becomes 1,000 mcg per mL. To draw a 200 mcg dose, you need 0.2 mL of the solution, which measures as exactly 20 units on a U-100 insulin syringe.
Does Ipamorelin's smaller peptide structure influence its properties?
Yes, its structure as a pentapeptide makes it one of the smallest molecules in the GHRP class. This minimalism is a key element of its design, contributing to its high binding specificity for the ghrelin receptor and its 'clean' profile, which minimizes the off-target receptor interactions seen with larger, more complex secretagogues.
Is the lack of a hunger response a sign that Ipamorelin is not working?
No, the absence of hunger is a designed-in feature and a direct confirmation of Ipamorelin's selectivity. It successfully uncouples the GH-releasing action from the separate ghrelin-mediated hunger signaling that is a hallmark of GHRP-6. The peptide's activity is determined by its effect on GH levels, not by the presence or absence of secondary effects.
What is the significance of scheduling doses in a fasted state?
Administering Ipamorelin on an empty stomach is a standard element of research protocols because the presence of food, especially carbohydrates and fats, can trigger the release of insulin. Insulin can in turn stimulate somatostatin, a hormone that inhibits growth hormone secretion from the pituitary. Dosing in a fasted state avoids this potential blunting effect on the GH pulse.
Why is ipamorelin administration often timed around fasting in research settings?
Many research protocols document ipamorelin administration during a fasted state due to the interaction between insulin and growth hormone. The GH pulse stimulated by ipamorelin can be partially blunted by elevated insulin levels, which typically occur after consuming a meal, especially one rich in carbohydrates. To study its effects under consistent physiological conditions, researchers often schedule administrations at times when insulin levels are expected to be at a baseline, such as upon waking or several hours after a meal. Logging the prandial state at the time of administration is a way to track this variable.
What specifically makes ipamorelin a 'selective' GH secretagogue?
Ipamorelin is considered selective because it was specifically designed to stimulate growth hormone release with minimal to no effect on other hormones like cortisol and prolactin at standard research dosages. Its development by Novo Nordisk in the 1990s aimed to improve upon earlier GHRPs, which were observed to cause elevations in these other hormones. This selectivity allows researchers to study the effects of GH elevation in a more isolated manner, without the confounding variables of simultaneous increases in stress hormones or prolactin.
Does the selectivity of ipamorelin change with the dose amount?
In scientific literature, the selectivity of ipamorelin for the GH axis is often noted as being dose-dependent. While standard research doses are observed to have minimal impact on cortisol and prolactin, studies involving very high, supramaximal doses have sometimes documented a loss of this selectivity. This means that at extremely large dosages, some stimulation of cortisol and prolactin might be observed. Therefore, when researchers plan a study, the dosage is a critical parameter to control and document, as it directly relates to the compound's selective properties.

Related on Peptide Pilot

Log every Ipamorelin dose in the app

Download on the App Store
Get the App